Veracyte has started a European consensus study that will explore the medical utility of multiple breast cancer genomic tests. Coordinated by Dr. Giuseppe Curigliano, PhD, from the European Institute of Oncology in Milan, the Procure study will have input from 180 breast cancer clinicians practicing in 12 countries.
As of yet, there is no consensus in the breast cancer community about the utility and ideal application of genomic tests. Curigliano and colleagues will use the Delphi method to facilitate consensus, which includes at least two rounds of a structured questionnaire. Consensus is reached by grouping participants' responses after each wave of questioning.
Over approximately 12 months, the study will comprehensively evaluate the existing evidence supporting the use of breast cancer genomic tests and the added value that clinicians attribute to them. The researchers will also assess the current use of these tools in patients with differing clinical-pathological profiles, establish recommendations on their use, and discuss future clinical applications and research opportunities.
